Benzinga | Jun 17, 2021 09:25AM EDT

Wedbush Maintains Outperform on Blueprint Medicines, Lowers Price Target to $130

Wedbush analyst Liana Moussatos maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and lowers the price target from $136 to $130.Wedbush analyst Liana Moussatos maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and lowers the price target from $136 to $130.